Tumor PD-L2 expression may predict patient response to anti-PD-1 immunotherapy

(American Association for Cancer Research) PD-L2 protein expression in human tumors was associated with clinical response to pembrolizumab (Keytruda), an anti-PD-1 immunotherapy, independent of PD-L1 expression, in patients with head and neck squamous cell carcinoma (HNSCC).
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news